Melbourne, Australia-based Paradigm Biopharmaceuticals Limited operates as a drug repurposing company, focusing on the discovery and development of therapeutic products for human application. The company's core offering is an injectable formulation of pentosan polysulfate sodium (PPS), which is being developed to address various medical conditions including osteoarthritis, mucopolysaccharidosis, Ross River virus, Chikungunya virus, and acute respiratory distress syndrome. The company was established in 2014.
—
Melbourne, Australia-based Paradigm Biopharmaceuticals Limited operates as a drug repurposing company, focusing on the discovery and development of therapeutic products for human application. The company's core offering is an injectable formulation of pentosan polysulfate sodium (PPS), which is being developed to address various medical conditions including osteoarthritis, mucopolysaccharidosis, Ross River virus, Chikungunya virus, and acute respiratory distress syndrome. The company was established in 2014.
—
Daily adjusted close
Melbourne, Australia-based Paradigm Biopharmaceuticals Limited operates as a drug repurposing company, focusing on the discovery and development of therapeutic products for human application. The company's core offering is an injectable formulation of pentosan polysulfate sodium (PPS), which is being developed to address various medical conditions including osteoarthritis, mucopolysaccharidosis, Ross River virus, Chikungunya virus, and acute respiratory distress syndrome. The company was established in 2014.